TrialStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Trial details
- Registry ID
- NCT06881784
- Phase
- Phase 3
Drug research
daraxonrasib
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 | RVMD | Phase 3 | Recruiting | 2027-12-01Estimated |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07491445 | RVMD | Phase 3 | Recruiting | 2028-06Estimated |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)NCT07252232 | RVMD | Phase 3 | Recruiting | 2029-05-10Estimated |
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Trial details
- Registry ID
- NCT07491445
- Phase
- Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Trial details
- Registry ID
- NCT07252232
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |